Table 1.
Baseline characteristics of cases and controls.
| Title | Cases | Controls | Total | p-Value |
|---|---|---|---|---|
| (N = 11) | (N = 22) | (N = 33) | ||
| Age | 63.64 (11.79) | 64.77 (11.92) | 64.39 (11.70) | 0.764 |
| Sex | 1.000 | |||
| Males | 2 (18.2%) | 4 (18.2%) | 6 (18.2%) | |
| Females | 9 (81.8%) | 18 (81.8%) | 27 (81.8%) | |
| Drug | 1.000 | |||
| Capecitabine | 7 (63.6%) | 14 (63.6%) | 21 (63.6%) | |
| 5-FU | 4 (36.4%) | 8 (36.4%) | 12 (36.4%) | |
| Strategy | 0.618 | |||
| Monotherapy | 4 (36.4%) | 10 (45.5%) | 14 (42.4%) | |
| Combined | 7 (63.6%) | 12 (54.5%) | 19 (57.6%) | |
| Carcinoma location | 0.313 | |||
| Breast | 3 (27.3%) | 6 (27.3%) | 9 (27.3%) | |
| Large bowel | 6 (54.5%) | 16 (72.7%) | 22 (66.7%) | |
| Stomach | 2 (18.2%) | 0 (0%) | 2 (6%) |
Data are presented as mean (standard deviation) or as count (percentage of total).